Institut de Chimie Moléculaire et des Matériaux d'Orsay

Charles Skarbek

Post doctorant
Bât. 670, bureau 102 – LCBB – ICMMO - UMR 8182
Université Paris-Saclay
Bâtiment 670
17-19 Avenue des Sciences
91400 Orsay
FRANCE

+33 1 69 15 47 25
charles.skarbek@u-psud.fr

Tapez du texte ici.

Synthesis of 6-methylphenanthridines and evaluation against human papillomavirus-related endocervical adenocarcinoma (KB 3.1) cells. H. Maslah, C. Skarbek, R. Labruère, Phytochem. Lett., 2023, 54, 146-152

Re-designing environmentally persistent pharmaceutical pollutant through programmed inactivation: The case of methotrexate. A. Espinosa, E. Rascol, M. A. Flos, C. Skarbek, P. Lieben, E. Bannerman, A. D. Martinez, S. Pethe, P. Benoit, S. Nélieu, R. Labruère, Chemosphere, 2022, 306, 135616

Photodegradation of methotrexate in aqueous solution: degradation kinetics and identification of transformation products. A. Espinosa, S. Nélieu, P. Lieben, C. Skarbek, R. Labruère, P. Benoit, Environ. Sci. Pollut. Res., 2022, 29, 6060-6071

In-cell generation of anticancer phenanthridine through bioorthogonal cyclization: a paradigm in antitumor prodrug development. H. Maslah, C. Skarbek, C. Gourson, M.-A. Plamont, S. Pethe, L. Jullien, T. Le Saux, R. Labruère, Angew. Chem. Int. Ed., 2021, 60, 24043-24047

Structural modification and biological activity studies of Tagitinin C and its derivatives. T. H. Au, C. Skarbek, S. Pethe, R. Labruère, J.-P. Baltaze, T. P. Hoa Nguyen, T. T. H. Vu, G. Vo-Thanh, Tetrahedron, 2021, 92, 132248

Anticancer boron-containing prodrugs responsive to oxidative stress from the tumor microenvironment. H. Maslah, C. Skarbek, S. Pethe, R. Labruère, Eur. J. Med. Chem., 2020, 207, 112670

Arylboronate prodrugs of doxorubicin as promising chemotherapy for pancreatic cancer. C. Skarbek, S. Serra, H. Maslah, E. Rascol, R. Labruère, Bioorg. Chem., 2019, 91, 103158